Did you find this information helpful?
Salt Composition : Sucroferric Oxyhydroxide
Manufacturer : EMCURE PHARMACEUTICALS LTD
Origin of Medicine : India
6 Tablet(s) In A Strip
Get financial assistance directly from pharma companies and cover your cost of medicines or get free medicines for the eligible patient with patient assistance programs (PAP). We provide proper guidance assistance to patients getting enrolled in the patient assistance program.
Introduction to Dynulta Tablet
Dynulta Tablet contains the active component sucroferric oxyhydroxide. It is classified as a phosphate binder. This medication treats hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. Hyperphosphatemia is characterized by abnormally high levels of phosphate in the blood, a common complication of CKD. This medicine contains iron, which can benefit individuals with CKD who often experience iron deficiency anemia. Providing iron and phosphate binding helps address iron deficiency and support red blood cell production.
You should not take Dynulta Tablet if you are allergic to it or its components. Allergic reactions can range from mild to severe and may include symptoms such as rash, itching, swelling, dizziness, or difficulty breathing. Patients with iron overload disorders, such as hemochromatosis (iron overload disorder), or those receiving high-dose intravenous iron therapy should use Dynulta Tablet cautiously. The use of this medicine in pediatric patients has not been extensively studied, and its safety and effectiveness in this population have yet to be established.
Uses of Dynulta Tablet
- Treatment of high phosphate levels in the blood
Therapeutic Effects of Dynulta Tablet
Dynulta Tablet is a medication that effectively lowers elevated phosphate levels in the blood, primarily in patients with chronic kidney disease (CKD) who are on dialysis. By binding to dietary phosphate in the gastrointestinal tract, this medication prevents its absorption into the bloodstream, thereby reducing the overall phosphate burden. This helps to manage hyperphosphatemia, a common complication of CKD, and minimize associated risks such as bone disease and cardiovascular complications.
Interaction of Dynulta Tablet with other drugs
Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Dynulta Tablet, reducing effectiveness by causing undesirable side effects.
More Information about Dynulta Tablet
- Stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F).
- Keep away from moisture, heat, and light.
- It should not be frozen.
- Keep away from children and pets.
How to consume Dynulta Tablet
To use Dynulta Tablet, follow the instructions provided by your healthcare professional or the guidelines on the medication packaging. Typically, this medication is taken orally as chewable tablets with meals or shortly after eating. The dosage and frequency of administration will depend on your specific medical condition and individual needs. It is important to chew the tablets thoroughly before swallowing. You may consult your healthcare provider for alternative administration options if you have difficulty chewing.
Safety Advices for Dynulta Tablet
The safety of Dynulta Tablet during pregnancy has not been well established, and there is limited clinical data regarding its use in pregnant women. Therefore, caution is advised when considering the use of this medication during pregnancy.
The safety of Dynulta Tablet during breastfeeding has not been well studied, and there is limited information on its excretion into human breast milk. Therefore, caution is advised when considering the use of breastfeeding.
Dynulta Tablet is not known to have specific safety concerns related to the lungs. If you have a pre-existing lung condition or are concerned about the safety of this medication in relation to your lungs, it is important to discuss your concerns with your healthcare provider.
The safety of Dynulta Tablet in individuals with liver disease has not been extensively studied. If you have liver disease or concerns about the safety of your liver, it is important to discuss these concerns with your healthcare provider.
Excessive alcohol consumption can negatively affect your health, especially if you have underlying liver disease or other medical conditions. Alcohol can also contribute to dehydration, which may affect the management of certain medical conditions.
Dynulta Tablets can cause side effects that may impair your ability to drive or operate machinery safely. Common side effects are drowsiness and dizziness. These effects can affect your coordination, reaction time, and judgment, making driving unsafe or performing tasks requiring alertness.
Side Effects of Dynulta Tablet
Dynulta tablets cause some side effects like all medications, although not everyone will experience them.
- Allergic reaction
- Black stools
- Discolored feces (usually dark or black)
- Stomach pain or discomfort
- Indigestion or heartburn
Word of Advice
When taking Dynulta Tablet, it is important to note that allergic reactions are rare, but when to occur it requires immediate medical attention for symptoms like rash, itching, swelling, difficulty breathing, or dizziness develop. This medication contains iron and may contribute to iron overload, particularly in at-risk individuals, necessitating regular monitoring of iron levels. Caution should be exercised in individuals with gastrointestinal disorders. The safety during pregnancy, breastfeeding, and in pediatric patients has not been well established. Precautions should be taken to minimize the risk of tooth discoloration by performing good oral hygiene practices. Regular communication with healthcare providers is essential to address concerns and promptly report any concerning symptoms or side effects.
Q 1. Can Dynulta Tablet cause interactions with certain laboratory tests or diagnostic procedures?
Dynulta tablets may interfere with certain laboratory tests that measure iron or phosphate levels. It is important to inform healthcare professionals performing these tests that you are taking this medication, as they may need to consider potential interference or make adjustments to the testing methodology.
Q 2. Can Dynulta Tablet be used in patients with kidney dysfunction?
Dynulta Tablet is primarily used in patients with chronic kidney disease who are on dialysis. However, in patients with severe kidney dysfunction who are not on dialysis, the use of this medication may need to be carefully evaluated by a healthcare provider due to the potential accumulation of the medication and associated risks.
Q 3. Can Dynulta Tablet be used in patients with a history of gastrointestinal bleeding or ulcers?
The use of Dynulta Tablet in patients with a history of gastrointestinal bleeding or ulcers should be cautiously approached. It is important to discuss your medical history with your healthcare provider, who can evaluate the potential risks and benefits of using this medication in your specific case.
Q 4. Can Dynulta Tablet be used in elderly patients?
Dynulta Tablets can be used in elderly patients; however, caution should be exercised due to the increased likelihood of age-related conditions and potential interactions with other medications commonly taken by older individuals. Your healthcare provider will consider your overall health and individual circumstances to determine the appropriate use of this medication in elderly patients.
Q 5. Can Dynulta Tablet be used long-term?
Dynulta Tablet is often used as a long-term treatment for chronic kidney disease in patients on dialysis. Your healthcare provider will determine the duration of treatment based on your individual needs and response to therapy. Regular follow-up visits will allow your healthcare provider to assess the ongoing efficacy and safety of this medication for your condition.
Q 6. What should I do if I experience side effects while taking Dynulta Tablet?
If you experience any side effects while taking Dynulta Tablet, it is important to report them to your healthcare provider promptly. They can evaluate the symptoms and determine the appropriate course of action.
Fact Box of Dynulta Tablet
Molecule name: Sucroferric oxyhydroxide
Therapeutic class: Phosphate lowering agent
Pharmacological class: Phosphate binders
|Indications: High Phosphate Levels in Blood|
- Vifor Fresenius Medical Care Renal Pharma France, Electronic medicines compendium (EMC), [Revised on Nov 2020] [ Accessed on 22nd June 2023], https://www.medicines.org.uk/emc/files/pil.3532.pdf
- Fresenius Medical Care North America, US Food and Drug Administration, [Revised on Sept 2014] [ Accessed on 22nd June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.